Bioeq Collaborates with Teva to Commercialize FYB201 (biosimilar, ranibizumab)

Shots:

Polpharma reported that its JV with Santo Holding, Bioeq has concluded a commercial partnership with Teva for their biosimilar candidate of the ophthalmological drug Ranibizumab (Lucentis) in the EU, Canada, Israel, and New Zealand
The agreement complements an existing agreement concluded with Coherus for the commercialization of the biosimilar in the US
FYB201 was originally licensed from Formycon and subsequently developed by Bioeq and has demonstrated efficacy in patients with nAMD is comparable to that of reference product, Lucentis

Click here to read full press release/ article | Ref: Businesswire| Image: Seeking Alpha